AMEA
Guardant Reveal demonstrates
high sensitivity
and specificity
in predicting
CRC recurrence.¹
Key findings from patients with longitudinally collected samples¹:
Explore additional findings from
the COSMOS-CRC-01 study.
CRC, colorectal cancer.
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.